Regeneron Pharmaceuticals, Inc

ISIN US75886F1075 Symbol REGN Industry Biotechnology Sector Healthcare
Regeneron Pharmaceuticals Price
536.0USD 2.37%
1y Low: 441.0
1y High: 664.6
1y Low: 441.0
1y High: 664.6
Regeneron Pharmaceuticals Analyst Rating
Strong Buy
Strong Sell
Market Cap
49.7 B USD
Dividend Yield
Performance 1y
10.82 %

Regeneron Pharmaceuticals Stock Chart

Regeneron Pharmaceuticals Dividend Chart

Regeneron Pharmaceuticals Dividend Calendar

Year # Div. Div. Paid Div. Yield Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Regeneron Pharmaceuticals Performance

1 Week
1 Month
0.96 %
6 Months
8.67 %
Year to Date
9.50 %
1 Year
10.82 %
5 Years
44.26 %

Regeneron Pharmaceuticals Revenue, EBIT, and Income

Regeneron Pharmaceuticals Margins

Regeneron Pharmaceuticals Shares Outstanding

Useful Links

Search Twitter: $REGN, #REGN

Regeneron Pharmaceuticals Company Info

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it is developing various product candidates for treating patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva; Mitsubishi Tanabe Pharma; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Vyriad, Inc., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; and BioNTech. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.

Regeneron Pharmaceuticals Headquarter

777 Old Saw Mill River Road, 10591 Tarrytown, NY, USA

Regeneron Pharmaceuticals Price to Earnings Ratio (PE Ratio): 15.2

The current Price to Earnings Ratio of Regeneron Pharmaceuticals is 15.2.
The PE Ratio is calcluated by dividing the current Regeneron Pharmaceuticals share price (536.0 USD) by the earnings per share (30.5).

Regeneron Pharmaceuticals Market Cap: 49.7 B USD

The current market cap of Regeneron Pharmaceuticals is 49.7 B USD.

Regeneron Pharmaceuticals Stock Price: 536.0 USD

The current stock price of Regeneron Pharmaceuticals is 536.0 USD.

Regeneron Pharmaceuticals ISIN: US75886F1075

The ISIN (International Securities Identification Number) of Regeneron Pharmaceuticals is US75886F1075.

Regeneron Pharmaceuticals Ticker Symbol: REGN

The ticker symbol of Regeneron Pharmaceuticals is REGN.

Regeneron Pharmaceuticals Address

The address of the Regeneron Pharmaceuticals HQ is 777 Old Saw Mill River Road, 10591 Tarrytown, NY, USA.